Joseph Vincenzo

Joseph Di Vincenzo (recorded in internal records as J. D. Di Vincenzo) is a clinical researcher specialising in rapid-acting treatments for mood disorders, with a primary focus on ketamine-based interventions. His work, drawn from real-world clinic cohorts, examines the effectiveness and safety of repeated intravenous ketamine infusions across diverse clinical populations — including transitional-age youth, patients with comorbid borderline personality disorder, bipolar depression and those at elevated suicidal risk. Di Vincenzo has contributed analyses of symptomatic worsening following ketamine administration and has characterised treatment responsiveness in routine clinical settings.

In addition to observational ketamine studies, Di Vincenzo has engaged in comparative effectiveness research within the emerging psychedelic therapeutics field, for example contributing to a systematic review comparing psilocybin and esketamine using number needed to treat (NNT) metrics. His publications emphasise pragmatic outcomes, tolerability, and applicability of rapid-acting interventions in heterogeneous, treatment-resistant populations, informing both clinical practice and future controlled investigations.